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ABSTRACT 
Background: In the United States, there is no well-established staging protocol for new breast 
cancer patients.  With various imaging modalities available, we performed the following 
systematic review and original retrospective study to better characterize the utility of bone scan, 
liver ultrasound, chest radiograph, and computed tomography (CT) of the abdomen.  For our 
systematic review, we determined the pooled detection rates of distant metastases using bone 
scan, liver ultrasound, and chest radiograph by clinical stage.  In our study, we determined the 
utility of further imaging with abdominal CT when there is no detected disease beyond the 
ipsilateral axillary lymph nodes by CT of the chest. 
Methods: As part of our systematic review, we searched PubMed and EMBASE databases for 
relevant articles using detection rate, defined as the number of patients with an abnormal test 
result divided by the total number of patients tested, as the primary outcome of interest for bone 
scan, liver ultrasound, and chest radiograph.  Additionally, for our retrospective study, we 
reviewed medical charts for 440 patients and used cross tabulation bivariate analysis to 
characterize the relationship between detection of disease in the chest and disease in the 
abdomen.   
Conclusion: Based on our systematic review, we believe that the routine use of bone scan, liver 
ultrasound, and chest radiograph in the staging evaluation of primary breast cancer patients is of 
little value in detecting metastatic disease in women with clinical stage I and stage II cancer due 
to very low detection rates.  Furthermore, we determined that of patients with no detectable 
disease in the chest beyond the ipsilateral axillary lymph nodes according to chest CT, 99.7% of 
them will have no detectable disease in the abdomen based on CT. 
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ABSTRACT 
 
Background: Routinely, radiological investigation with bone scan, chest radiograph, and liver 
ultrasound are employed as baseline staging tests. The aim of this review was to examine 
indications for this costly routine screening, and, thus, we posed the following question: Among 
women with newly diagnosed breast cancer who are otherwise asymptomatic, does evaluation 
with bone scanning, liver ultrasound, and chest radiograph help to determine the extent of 
metastatic disease? 
Methods: We searched PubMed and EMBASE databases to find articles using detection rate, 
defined as the number of patients with an abnormal test result divided by the total number of 
patients tested, as the primary outcome of interest.  In order to obtain overall estimates of 
detection rates in each test, the results from the studies were pooled and summed according to 
pathological stage.   
Results: Eight articles out of 232 reviewed were included in the final analysis.  The following 
pooled detection rates for bone scan were calculated according to stage: Stage I 7 of 544 
(1.29%), Stage II 29 of 938 (3.09%), Stage I & II 36 of 1,482 (2.43%), and Stage III 39 of 312 
(12.5%).  For liver ultrasound: Stage I 1 of 213 (0.47%), Stage II 4 of 400 (1.00%), Stage I & II 
5 of 613 (0.82%), and Stage III 6 of 143 (4.20%).  And, for chest radiograph: Stage I 0 of 223, 
Stage II 2 of 473 (0.42%), Stage I & II 9 of 1,782 (0.51%), and Stage III 8 of 175 (4.57%). 
Conclusion: The routine use of bone scan, liver ultrasound, and chest radiograph in the staging 
evaluation of primary breast cancer patients is of little value in detecting metastatic disease in 
women with clinical stage I and stage II cancer, and therefore, should not be performed. 
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INTRODUCTION 
 
 Staging is pivotal in the management of cancer and describes the extent and severity of 
the patient’s disease.  By classifying a person’s stage, a more accurate treatment plan and 
estimate of the patient’s prognosis may be determined.1,2  Carcinoma of the breast commonly 
metastasizes to bone, lung, liver, and brain.
1
  To detect the presence of disease at these distant 
sites, many expensive imaging modalities with increasing sensitivity and specificity are utilized 
by providers; however, as the care of cancer patients becomes more complex, the need for cost 
containment is paramount to the health care system.  In response, providers must find areas to 
eliminate expensive staging techniques, while also protecting patient safety and providing 
accurate staging and diagnosis of disease.   
Routinely, radiological investigation with bone scan, chest radiograph, and liver 
ultrasound are employed as baseline staging tests and are commonly referred to as “conventional 
diagnostic procedures”.3,4  The aim of this review was to examine indications for this costly 
routine screening, and, thus, we posed the following question: Among women with newly 
diagnosed breast cancer who are otherwise asymptomatic, does evaluation with bone scanning, 
liver ultrasound, and chest radiograph help to determine the extent of metastatic disease?
5 
 
METHODS 
 
Search Design & Study Criteria 
  
PubMed and EMBASE databases were searched without language restriction or 
limitations on publication date, using the terms “bone scan”, “bone neoplasms/radionuclide 
imaging”, “liver ultrasound”, “chest radiograph”, “chest x-ray”, “diagnosis metastatic”, 
“detection metastatic”, “primary breast cancer”, and “primary breast neoplasm” as keywords.  
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Specifically, in EMBASE, the term “bone scintiscanning” was added to the search.  
Bibliographies from relevant articles were also reviewed.  Only retrospective case series were 
included.  To account for the rapid progression of the sensitivity and specificity of imaging 
modalities and in order to provide more accurate results from current technology, articles were 
reviewed if published after 1990.  Furthermore, studies unavailable in English were excluded 
from the study. 
Abstracts of relevant articles were reviewed if they reported number of women with 
newly diagnosed breast cancer who had disease detected by bone scan, liver ultrasound, or chest 
radiograph. Studies were included only if they reported rates of positive tests by patient’s 
pathological stage by the TNM staging system.   These tests could be performed prior to or after 
surgical intervention. 
 
Study Evaluation 
 A single author evaluated the articles selected for full review.  The pertinent study data 
was extracted and organized into Tables 1 and 2, including setting, study method, total 
population, outcome measure, and total pooled results by method.  The study’s quality was 
assessed using a grading criteria consisting of 4 categories: (1) reporting of all disease stages, (2) 
applicability to population of interest, (3) sufficient protocol detail, and (4) sufficient reporting of 
results with confidence limits.  Each criterion was weighted equally and assigned a grade of 
good, fair, or poor (good = 2, fair = 1, poor = 0).  These categorical scores were then averaged to 
give a final quality score that is presented in Table 2 (good > 1.5, fair 1.0 – 1.49, poor < 1.0).   
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Data Synthesis 
The primary outcome of interest was the detection rate, defined as the number of patients 
with an abnormal test result divided by the total number of patients tested.  In order to obtain 
overall estimates of detection rates in each test, the results from the studies were pooled and 
summed according to pathological stage.
5 
 
RESULTS 
 As seen in Figure 1, results from PubMed and EMBASE searches yielded a total of 232 
articles, without duplicates.  These 232 articles were screened on the basis of title and abstract 
relevance, which provided 6 articles for full study review.  Of the 226 articles excluded from the 
review, 207 articles did not measure detection rate as their outcome, 3 articles were not provided 
in English, and 15 articles were published prior to 1990.  
 The bibliographies of the 6 articles were reviewed for relevant titles, which yielded 5 
additional articles.  After review of the full manuscripts, 8 articles were included for the final 
analysis.  Three articles were excluded.  Two studies did not provide the detection rate by 
pathological stage,
6,7
and one study did not report detection rate as the outcome measure.
8
   
 Of the studies present in the final analysis, four studies analyzed only bone scanning; one 
study analyzed only chest radiography; three studies reviewed all three imaging modalities.  
 
Bone Scanning 
 As seen in Table Three, seven studies reported the detection rate of bone metastasis 
using routine bone scan.  The calculated rate was reported by stage (Stage I, Stage II, Stage I & 
II, Stage III) for each study.  The pooled rates for all studies are provided by stage as well.  For 
patients with Stage I disease, only 1.29% (7/544) were found to have metastatic or possible 
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metastatic disease to the bone as detected by bone scintigraphy.  Similarly, only 3.09% (29/938) 
of patients with Stage II tumors had detectable or possible disease spread to bone as detected by 
bone scan.  A pooled detection rate of only 2.43% (36/1,482) was determined for Stage I and II 
cancers.  Patients with Stage III tumors had a larger number of detected bone metastasis at 
12.50% (39/312).  In total, across all three stages, bone scan detected disease spread in 4.18% 
(75/1,794) of new breast cancer patients. 
Liver Ultrasound 
 As seen in Table Four, three studies reported the detection rate of liver metastasis using 
routine liver ultrasound.  The calculated rate was reported by stage (Stage I, Stage II, Stage I & 
II, Stage III) for each study.  The pooled rates for all studies are provided by stage as well.  For 
patients with Stage I disease, only 0.47% (1/213) were found to have metastatic or possible 
metastatic disease to the liver as detected by ultrasound.  Similarly, only 1.00% (4/400) of 
patients with Stage II tumors had detectable or possible disease spread to the liver as detected by 
ultrasound.  A pooled detection rate of only 0.82% (5/613) was determined for Stage I and II 
cancers.  Patients with Stage III tumors had only 4.20% (6/143) of patients with detected liver 
metastasis.  In total, across all three stages, liver ultrasound detected disease spread in 1.34% 
(11/822) of new breast cancer patients. 
Chest Radiograph 
 As seen in Table Five, four studies reported the detection rate of pulmonary metastasis 
using routine chest X-ray.  The calculated rate was reported by stage (Stage I, Stage II, Stage I & 
II, Stage III) for each study.  The pooled rates for all studies are provided by stage as well.  For 
patients with Stage I disease, none of the study patients were found to have metastatic or possible 
metastatic disease to the lung as detected by radiograph.  Similarly, only 0.42% (2/473) of 
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patients with Stage II tumors had detectable or possible disease spread to the lung as detected by 
chest X-ray.  A pooled detection rate of only 0.51% (9/1,782) was determined for Stage I and II 
cancers.  Patients with Stage III tumors had a higher percentage of patients with potential lung 
metastasis at 4.57% (8/175).  In total, across all three stages, a routine chest radiograph detected 
possible disease spread to the lung in 0.87% (17/1,957) of new breast cancer patients. 
 
CONCLUSION 
 Many previous studies have evaluated the use of CDPs (bone scanning, liver ultrasound, 
and chest radiograph) in primary breast cancer staging.  With all methods, the detections rates 
increased with tumor size; however, the overall detection rates remain low for all three 
modalities, particularly in asymptomatic patients, which questions the utility of these imaging 
exams.  Moreover, these techniques do not include many of the other common sites of 
metastasis.  Many studies have recommended limited use of CDPs, particularly in patients with 
smaller tumor sizes.
5, 6, 8, 13, 15
  
Future Research 
 The strength of this study is mainly a result of the number of patients studied – 1,794 for 
bone scan, 822 for liver ultrasound, and 1,957 for chest radiograph – and the consistently low 
detection rates seen for each method; however, further research to determine the false negative 
and false positive rates are needed to fully ascertain the usefulness of these methods as baseline 
staging exams.  Moreover, the differences in rates of detection in patients who are clinically 
symptomatic versus asymptomatic would be helpful in determining if particular subgroups of 
cancer patients would benefit from these types of screening techniques.   
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Recommendations 
 Based on this data, the detection rates in patients with Stage I & Stage II tumors are 
incredibly low, with 0.50% to 3.00% detection rates among the three methods.  With such a low 
number, we question if there is significant utility in performing any CDP on patients with small 
tumors, T1 and T2, who are clinically asymptomatic.  Further research can more clearly answer 
this question, but the consensus of this research group is that patients with clinically early 
cancers do not benefit from bone scanning, chest radiograph, or liver ultrasound.  It is our 
recommendation that asymptomatic patients proceed with only a screening chest CT scan.  
Further evaluation with abdominal and pelvic CT scans should only be performed in the presence 
of disease spread beyond the axillary lymph nodes or if the patients presents with specific 
symptomatology concerning for metastatic disease in these regions.
5
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TABLES & FIGURES 
Figure One: Literature Search Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Literature Search: 
Databases: PubMed & EMBASE 
Limitations: None 
Literature Search: 
Databases: PubMed & EMBASE 
Limitations: None 
Search Results: (n = 232) 
PubMed: 223  
EMBASE: 9  
Duplicates: 0  
 
Articles screened on basis of title 
and abstract (n = 6 ) 
Excluded: (n = 226) 
Different outcome measure: 208 
Articles not provided in English: 3 
Articles published before 1990: 15 
Included: 11 
Articles provided from 
screened bibliographies 
(n = 5) 
 
Manuscript review and application 
of inclusion criteria Excluded: (n = 3) 
Did not meet inclusion criteria: 
Gerber, et. al. (2003)
6
 
Hadley, et. al. (1998)
8
 
Muller, et. al. (2008)
7
 
 
Included: 8 
Liver U/S: 
Glynne-Jones, et. al. (1991)
11
 
Barry, et. al. (1999)
14
 
Schneider, et. al. (2002)
16
 
Bone Scan: 
Ahmed, et. al. (1990)
9
 
Brar, et. al. (1991)
10
 
Glynne- Jones, et. al. (1991)
11
 
Kennedy, et. al. (1991)
12
 
Yeh, et. al. (1995) 
13
 
Barry, et. al. (1999)
14
 
Schneider, et. al. (2002)
16 
CXR: 
Glynne-Jones, et. al. (1991)
11
 
Barry, et. al. (1999)
14
 
Chen, et. al. (2000)
15
 
Schneider, et. al. (2002)
16
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Table 1: Summary of Included Studies and Type of Test Measured 
Source Method* Patients, 
n 
Bone 
Scan 
Liver 
Ultrasound 
Chest 
Radiograph 
 
9
Ahmed, et. al. (United Kingdom, 1990) 
 
RCR 
 
389 
 
x 
  
 
10
Brar, et.al. (USA, 1991) 
 
RCR 
 
131 
 
x 
  
 
11
Glynne-Jones, et. al. (United Kingdom, 1991) 
 
RCR 
 
389 
 
x 
 
x 
 
x 
 
12
Kennedy, et. al. (United Kingdom, 1991)
 
 
RCR 
 
84 
 
x 
  
 
13
Yeh, et. al. (USA 1995) 
 
RCR 
 
316 
 
x 
  
 
14
Barry, et. al. (Ireland, 1999) 
 
RCR 
 
82 
 
x 
 
x 
 
x 
 
15
Chen, et. al. (USA, 2000) 
 
RCR 
 
1,085 
   
x 
 
16
Schneider, et. al. (Switzerland , 2002) 
 
RCR 
 
485 
 
x 
 
x 
 
x 
*RCR = Retrospective Chart Review 
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Table 2: Summary of Study Design Characteristics 
Study  Population* Method Outcome 
Measure 
Results 
(%, n) 
Quality 
Rating
$
 
  
9
Ahmed, et. al.  Asymp. new 
BRCA pts. 
 
RCR Detection 
Rate 
Bone Scan: 18.77 (24/389) 1.75   
10
Brar, et.al.  Asymp. new 
BRCA pts. 
 
RCR Detection 
Rate 
Bone Scan: 3.10 (4/131) 
 
1.25   
11
Glynne-Jones  Asymp. new 
BRCA pts. 
 
RCR Detection 
Rate 
Bone Scan: 6.17 (24/389) 
Liver U/S
#
: 2.30 (6/261) 
Chest X-ray: 2.07 (8/386) 
 
2.00   
12
Kennedy, et. al
 
 Asymp. new 
BRCA pts. 
 
RCR Detection 
Rate 
Bone Scan: 3.57 (3/84) 1.75   
13
Yeh, et. al.  Asymp. new 
BRCA pts. 
 
RCR Detection 
Rate 
Bone Scan: 2.20 (7/316) 1.25   
14
Barry, et. al.  Asymp. new 
BRCA pts. 
 
RCR Detection 
Rate 
Bone Scan: 1.26 (1/79) 
Liver U/S: 0.00 (0/76) 
Chest X-ray: 1.22 (1/82) 
 
1.25   
15
Chen, et. al.  Asymp. new 
BRCA pts. 
 
RCR Detection 
Rate 
Chest X-ray: 0.60(6/1,004) 1.25   
16
Schneider, et. al.  Asymp. new 
BRCA pts. 
 
RCR Detection 
Rate 
Bone Scan: 2.68 (13/485) 
Liver U/S: 1.03 (5/485) 
Chest X-ray: 0.41 (2/485) 
1.75   
*Asymptomatic, new breast cancer patients 
#
U/S = Ultrasound 
$The study’s quality was assessed using a grading criteria consisting of 4 categories: (1) reporting of all disease 
stages, (2) applicability to population of interest, (3) sufficient protocol detail, and (4) sufficient reporting of results.  
Mean score is reported as the Quality Rating (good > 1.5, fair 1.0 – 1.49, poor < 1.0).   
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Table 3: Bone Scan Results by Stage of Breast Cancer  
                               Cancer Stage; % (and no.) of patients with abnormal scan results  
Study Year Stage I Stage II Stage I & II Stage III Total 
 
9
Ahmed, et. al. 
 
1990 
 
2.50 (2/80) 
 
4.00 (9/226) 
 
3.59 (11/306) 
 
15.66 (13/83) 
 
18.77 (24/389) 
 
10
Brar, et. al. 
 
1991 
 
0 (0/21) 
 
3.00 (2/67) 
 
2.27 (2/88) 
 
4.70 (2/43) 
 
3.10 (4/131) 
 
11
Glynne- Jones
 
 
1991 
 
1.50 (1/67) 
 
4.20 (10/240) 
 
3.58 (11/307) 
 
16.00 (13/82) 
 
6.17 (24/389) 
 
12
Kennedy, et. al 
 
1991 
 
0 (0/13) 
 
1.67 (1/60) 
 
1.37 (1/73) 
 
18.18 (2/11) 
 
3.57 (3/84) 
 
13
Yeh, et. al.  
 
1995 
 
1.00 (2/204) 
 
4.50 (5/112) 
 
2.20 (7/316)  
 
--- 
 
2.20 (7/316) 
 
14
Barry, et. al. 
 
1999 
 
--- 
 
--- 
 
1.26 (1/79) 
 
--- 
 
1.26 (1/79) 
 
16
Schneider, et. al.  
 
2002 
 
1.30 (2/159) 
 
0.80 (2/233) 
 
1.02 (4/392) 
 
9.70 (9/93) 
 
2.68 (13/485) 
 
All studies 
  
1.29 (7/544) 
 
3.09 (29/938) 
 
2.43(36/1,482) 
 
12.5 (39/312) 
 
4.18 (75/1794) 
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Table 4: Liver Ultrasonography Results by Stage of Breast Cancer  
                                           Cancer Stage; % (and no.) of patients with abnormal results  
Study Year Stage I Stage II Stage I & II Stage III Total 
 
11
Glynne-Jones 
 
1991 
 
1.80 (1/54) 
 
1.80 (3/167) 
 
1.80 (4/221) 
 
4.00 (2/50) 
 
2.30 (6/261) 
 
14
Barry, et. al.
 
 
1999 
 
--- 
 
--- 
 
0.00 (0/76) 
 
--- 
 
0.00 (0/76) 
 
16
Schneider, et. al. 
 
2002 
 
0 (0/159) 
 
0.40 (1/233) 
 
0.26 (1/392) 
 
4.30 (4/93) 
 
1.03 (5/485) 
 
All studies 
  
0.47 (1/213) 
 
1.0 (4/400) 
 
0.82 (5/613) 
 
4.20 (6/143) 
 
1.34(11/822) 
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Table 5: Chest Radiography Results by Stage of Breast Cancer  
                                          Cancer Stage; % (and no.) of patients with abnormal results  
Study Year Stage I Stage II Stage I & II Stage III Total 
 
11
Glynne-Jones 
 
1991 
 
0 (0/64) 
 
0.80(2/240) 
 
0.65 (2/304) 
 
7.30 (6/82) 
 
2.07 (8/386) 
 
14
Barry, et. al. 
 
1999 
 
--- 
 
--- 
 
1.22 (1/82) 
 
--- 
 
1.22 (1/82) 
 
15
Chen, et. al. 
 
2000 
 
--- 
 
--- 
 
0.60 (6/1,004) 
 
--- 
 
0.60(6/1,004) 
 
16
Schneider, et. al. 
 
2002 
 
0 (0/159) 
 
0 (0/233) 
 
0 (0/392) 
 
2.20 (2/93) 
 
0.41 (2/485) 
 
All studies 
  
0 (0/223) 
 
0.42(2/473) 
 
0.51 (9/1,782) 
 
4.57(8/175) 
 
0.87(17/1,957) 
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ABSTRACT 
Objective:  As there is currently no well-established staging protocol for primary breast cancer, 
we sought to evaluate the role of computed tomography (CT), a commonly used imaging 
modality.  The purpose of this study was to determine the utility of routine abdominal CT in the 
staging evaluation of women with newly diagnosed primary breast cancer given no detectable 
disease beyond the ipsilateral axillary nodes on chest CT. 
Methods: The chest and abdominal CT scans from 440 patients over a 10-year period were 
reviewed.  The presence of definite or possible metastatic disease in the axillary nodes, chest 
wall, internal mammary nodes, mediastinal nodes, lungs, liver and adrenals were recorded for 
each patient.  Cross tabulation bivariate analysis as well as a chi-square test were performed to 
characterize the relationship between detection of disease in the chest and disease in the 
abdomen.   
Results: Of the 440 patients reviewed, the following were found to have detectable metastatic 
disease by CT scan: axillary nodes 258 of 440 (56.5%), chest wall 40 of 440 (9.1%), internal 
mammary nodes 8 of 440 (1.8%), mediastinal nodes 29 of 440 (6.6%), lung 25 of 440 (5.7%), 
liver 12 of 437 (2.7%), and adrenals 8 of 440 (1.8%).  In total, 81 patients had disease detectable 
in the chest beyond the ipsilateral axillary nodes (ie, chest wall, internal mammary nodes, 
mediastinal nodes, and lung), and only 12 patients had detectable disease spread in the abdomen 
(ie, liver and adrenals).  Of the 359 patients who had a negative chest CT, only 1 patient had 
detectable or possible metastatic disease spread on abdominal CT, resulting in a 99.7% negative 
predictive value (p < 0.001). 
Conclusion:  The routine use of abdominal CT in women with newly diagnosed primary breast 
cancer and no detectable disease beyond the ipsilateral axillary nodes on staging chest CT scan 
has a 99.7% negative predictive value.  Based on this information, we recommend that if a 
negative CT scan of the patient’s chest yields no detectable disease beyond the axillary nodes, 
then further CT imaging of the abdomen is of no additional benefit to the patient and should not 
be performed. 
 
 21 
INTRODUCTION 
Primary Breast Cancer Staging in the United States 
 Breast cancer is the most frequent malignant tumor in women of the Western countries.
1
 
In 2011, an estimated 230,000 women were diagnosed with a new invasive breast cancer in the 
United States.
1
 These patients will receive some form of staging evaluation at the time of their 
diagnosis.  Staging describes the extent and severity of the patient’s disease and is pivotal in the 
management of cancer.  A patient’s specific stage is based on the invasiveness of the cancer, the 
size of the tumor, the number of lymph nodes involved, and presence of distant metastasis.
2
 By 
classifying a person’s stage, a more accurate treatment plan and estimate of the patient’s 
prognosis may be determined.
3
 
 Several imaging techniques are among the various tests that are used during a staging 
evaluation.  Imaging technology is advancing at a rapid pace, with tests available that are 
increasingly more sensitive and specific in detecting morphologic as well as functional changes 
in anatomy.
4
 With these advances, however, comes the added expense to the medical system as 
well as to the patient, additional time consumption, and emotional toll.  In the U.S., there is no 
clearly defined and accepted protocol for staging of primary breast cancers.  Positron emission 
tomography (PET) and computed tomography (CT) are commonly used in addition to less 
advanced techniques such as ultrasound and radiography.
4,5
 Moreover, to our knowledge, no 
variations in imaging protocols exist based on the patient’s initial tumor size and axillary lymph 
node metastasis.
6
   
Sites of Distant Metastasis 
 Roughly 45%-50% of new breast cancer patients will develop detectable distant 
metastases.
7
  A woman’s individual risk for distant metastases may be based on various tumor 
 22 
factors, but most particularly, the presence and extent of disease spread to the axilla.
7
  Moreover, 
these findings have a significant impact on determining the therapeutic plan.  The most common 
sites for distant metastasis include lung, liver, brain, bone, and adrenals.
2
  Effective staging 
evaluation must utilize imaging or laboratory techniques that can assess these locations in 
totality.  
Conventional Diagnostic Procedures (CDPs) 
 The conventional diagnostic procedures (CDPs) include chest radiograph 
(posterior/anterior and lateral), ultrasound of the liver, and bone scan.  In many institutions, these 
modalities are commonly used to determine presence of metastases in the lung, liver, and bone, 
respectively.  The documented cumulative sensitivity of these tests may range from 36% to 51%, 
with a greater specificity ranging from 81% to 95%.
5
  One possible explanation for these 
suboptimal results is that metastases may be too small to detect with these methods.  Moreover, 
these conventional techniques do not examine other common sites of disease spread, including 
other thoracic lymph nodes or the adrenal glands.
8
 However, one study estimated the positive 
predictive value of CDPs to be as high as 91%, but a negative predictive value of 53%.
5
  
 Because CDPs are often inconclusive with low sensitivities, additional imaging may be 
needed to achieve a final diagnosis.  To further assess suspicious findings, providers may pursue 
computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography 
(PET), and/or bone scanning.  With this additional imaging comes added financial cost, radiation 
exposure, and an increase in a patient’s anxiety.  Regardless, CDPs continue to be mainstays in 
staging options as other imaging modalities are very costly, with longer scanning times and may 
not be available in all institutions.
5
    
 
 23 
Positron Emission Tomography (PET) 
 Positron emission tomography (PET) is a more advanced form of imaging that has been 
shown to be useful in detecting many tumors as well as distant metastases.  It is well-established 
in radiologic research that there is increased uptake of 2-[
18
F]fluoro-2-deoxy-D-glucose (FDG) 
in numerous malignancies.
5
  This increased uptake is evidence for enhanced glycolytic rate 
compared to the surrounding benign tissue.  As a result, FDG PET is another method used for 
whole-body staging evaluation.
5
  
 Few studies report data concerning use of FDG PET in detection of distant disease 
spread; however, results from one prospective study indicate that FDG PET has a superior 
sensitivity to CDPs (78.6%-100%) as well as higher specificity (89.4%-100%).
5
  Compared to 
CDPs, FDG PET has a comparable positive predictive value of 93% and a higher negative 
predictive value (83% vs. 53%).
5
  Although superior in disease detection, FDG PET is a costly 
method with long scanning times.  Furthermore, depending on the location, PET may not be 
widely available to all patients.
5,9
   
 Generally, based on few studies reviewing PET for whole-body staging, FDG PET is not 
recommended in patients with small primary tumors on imaging (defined as < 3cm) and negative 
lymph nodes, as determined by surgical dissection or sentinel lymph node biopsy.
5,9
 In contrast, 
it is recommended for those with locally advanced disease, extended lymph node metastases and 
those scheduled to undergo intense chemotherapy.  Furthermore, scanning is recommended in 
cases of uncertain radiographic results or rising tumor markers.
5
  In spite of these 
recommendations, many institutions continue to utilize PET in various ways, depending on 
availability and established practice.   
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The Role of Computed Tomography (CT) in Breast Cancer Staging 
The clinical experience of members of our multidisciplinary breast oncology program has 
been that CT is a commonly utilized modality at the University of North Carolina Hospitals 
(UNCH) as well as referring institutions for breast cancer staging.  Computed tomography is 
used to evaluate the chest, abdomen, and pelvis.  With CT of the chest, the following structures 
may be evaluated for disease spread: axillary lymph nodes, chest wall, mediastinal nodes, 
internal mammary nodes, and lung.  An abdominal CT will allow evaluation of the liver and 
adrenal glands, and the pelvic CT will allow visualizaiton of the ovaries, endometrium, and 
pelvic bone.   
In 2000, retrospective research from authors at Memorial Sloan-Kettering reported that 
patient treatment was not substantially altered based on findings from pelvic CT scans.
10
 
Moreover, findings were reported to lead to additional examinations and procedures that yielded 
normal, benign, or indeterminate results that were not relevant to the patient’s cancer therapy.  
Specifically, out of 2426 new primary breast cancer patients, only 17 patients (0.7%) were found 
to have metastatic disease isolated to the pelvis.  Of the 17 patients, eleven had metastasis 
present only in the pelvic bone, which was simultaneously detected by concomitant bone 
scanning.  Pelvic CT only contributed relevant information for six patients, who had disease 
present in the adnexa and/or endometrium.  As a result, routine scanning of the pelvis by CT was 
non-contributory in nearly all new cancer patients and, therefore, was not recommended based 
on these findings.
10
     
Likewise, it has been our anecdotal experience that evaluation of the abdomen yields no 
further information when no metastases are detected in the chest beyond the ipsilateral axillary 
lymph nodes.  Hence, we reviewed the evidence and indications for the extent of routine CT 
scanning in the context of the following hypothesis: If CT does not detect suspected spread of 
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disease beyond the ipsilateral axilla in the chest, then CT will not detect the spread of disease in 
the abdomen.  In other words, if a negative CT scan of the patient’s chest yields no detectable 
disease beyond the axilla, then further CT imaging of the abdomen is of no additional benefit to 
the patient and should not be performed. 
 
 
METHODS 
 
Patient Selection and Data Collection 
  
 With Internal Review Board (IRB) approval, we performed a retrospective case series of 
all patients seen in the multidisciplinary breast oncology program at the University of North 
Carolina Hospital (UNCH) between 1998 and 2011.  We reviewed clinical records in order to 
identify all patients referred for diagnosis of suspected breast cancer or treatment of a newly 
diagnosed primary breast cancer by fine needle aspiration, core biopsy, or excisional biopsy.  
Male patients, patients with a previous diagnosis of breast cancer, those with a diagnosis of 
benign breast disease, as well as those with a metastatic breast carcinoma from another primary 
cancer were excluded.  Patients referred after surgical intervention were also excluded. There 
was no age exclusion. 
 Patients with a CT scan of the chest and abdomen within 30 days of diagnosis were 
included in the review.  Patients evaluated with a CT chest or abdomen greater than 30 days after 
diagnosis were excluded.  Those referred with imaging studies from outside institutions that 
could not be reviewed were not included in the study.  Likewise, patients imaged at UNCH 
whose imaging exams could not be retrieved were excluded.  Furthermore, those evaluated for 
staging purposes using Positron Emission Tomography/Computed Tomography (PET/CT) scans, 
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either at UNCH or referring institutions, were excluded.  This provided a final study group of 
440 subjects.   
 CT scans were all performed on helical scanners and reconstructed with 5mm or 8mm 
slice thickness and table incrementation. Between 1999 and 2002, patients were imaged on a 
Siemens® Plus 4 scanner, which has a single detector with helical acquisition.  After 2002, all 
patients were imaged on a multidetector scanner, also with helical acquisition.  All CT scans 
were reviewed by a board certified chest radiologist with fellowship training in body computed 
tomography.  Scans of the chest were reviewed for the presence, questionable presence, or 
absence of axillary, mediastinal, and internal mammary adenopathy; chest wall invasion; and 
pulmonary metastases.  Scans of the abdomen were reviewed for presence, possible presence, or 
absence of hepatic and adrenal metastases.  Information from patient medical records included 
initial clinical stage, final pathologic stage post-operatively (if available), results of liver function 
tests (if determined), and findings from bone scan (if performed).   
 
Data Analysis 
 We used descriptive statistics to tabulate patient staging distribution and the presence of 
disease in the chest and abdomen as detected by CT scan.  The total number of patients included 
in the final analysis were calculated and categorized by their clinical stage.  Within each clinical 
stage, the number and percentage of patients with metastases to the axillary nodes, chest wall, 
internal mammary nodes, lung, mediastinal nodes, liver, and adrenal glands were also calculated.  
Additionally, for each clinical stage, the total number and percentage of patients who had 
detected presence of disease in either the chest or the abdomen were summed.  Cross tabulation 
bivariate analysis was performed to characterize the relationship between detection of disease in 
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the chest and detection of disease in the abdomen.  The following contingency tables provide 
matrix displays of each variable based on location of disease.  For contingency Table Two, a 
chi-square test was performed as a test for statistical significance. 
 
 
RESULTS 
Presence of Metastases by Anatomical Sites and Clinical Stage 
 For analysis, 440 patient scans were reviewed.  Each patient received a chest CT and an 
abdominal CT.  As seen in Table One, most patients were classified as stage IIB (129 of 440).  
The distribution by stage was as follows: Stage IIIA (90), Stage IIA (83), Stage IIIB (63), Stage I 
(40), and Stage IV (33).  Two patients diagnosed with in situ carcinoma by core biopsy 
underwent staging evaluation by CT. 
 In total, 258 (56.46%) patients had disease spread to the axillary lymph nodes as detected 
by CT chest.  Of note, axillary lymph node data was unavailable for 31 patients, as their CT 
evaluation was performed following surgical dissection.  By stage, data was missing for the 
following: in situ (0), Stage I (3), Stage IIA (10), Stage IIB (14), Stage IIIA (2), Stage IIIB (2), 
Stage IV (0).  These 31 patients were subtracted from the study population when calculating the 
percentage of metastases by stage and in total.   
 For other sites beyond the axillary lymph nodes, disease spread was less frequent: chest 
wall 40 (9.10%), internal mammary nodes 8 (1.82%), mediastinal nodes 29 (6.59%), lung 25 
(5.68%), liver 12 (2.73%), and adrenals 8 (1.82%).  For three patients, liver data was unavailable 
due to lack of contrast administration.  By stage, data was missing for the following: in situ (0), 
Stage 1 (0), Stage IIA (0), Stage IIB (1), Stage IIIA (1), Stage IIIB (1), Stage IV (0).  These 
 28 
patients were subtracted from the study population when calculating the percentage of metastases 
by stage and in total. 
 
Comparison of Disease Detection in the Chest versus Abdomen  
 
 As seen in Table Two, 359 of the 440 patients scanned did not have disease detected in 
structures beyond the axillary lymph nodes (ie, chest wall, internal mammary nodes, mediastinal 
nodes, lung) based on CT imaging.  Of these 359 patients without detectable disease in the chest, 
only 1 patient was found to have disease spread to the abdomen.  This patient had metastatic 
disease spread to the liver, but not detectable disease to the adrenals as noted in Tables Three 
and Four.  Moreover, PET/CT scanning of this patient found detectable disease spread in the 
supraclavicular, which was not present on chest CT. 
 From these data, a 99.7% negative predictive value was calculated.  In other words, of 
those who did not have disease detected beyond the axillary lymph nodes in the chest, 99.7% did 
not have detectable disease in the liver or adrenals (p<0.001).  
 
Comparison of Disease Detection by Individual Chest Structures versus Abdomen 
  As additional information, Tables Five through Eight display the contingency tables for 
each individual chest structure and disease spread to the abdomen.  Of note, out of the 12 
patients with detected abdominal metastases, 8 had detectable lung metastasis on CT scan.  The 
other chest structures had detectable disease with concomitant abdominal metastasis seen in the 
following number of cases: chest wall invasion (4), mediastinal nodes (4), and internal mammary 
nodes (2).   
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DISCUSSION 
 Once the initial diagnosis of invasive breast cancer is made, the extent of disease spread 
is assessed in order to inform appropriate therapy, patient prognosis, and formally stage the 
tumor.  This assessment includes a number of imaging modalities, such as chest radiograph, liver 
ultrasound, bone scintigraphy, MRI, PET, and CT scan of the chest, abdomen, and pelvis.  
Results from these various tests may also inform further imaging to reach a final diagnosis.  To 
our knowledge, the routine use of many of these staging techniques is not standardized with no 
well-established protocol.
10
   Our goal was to assess the role of abdominal computed tomography 
in staging primary breast cancer patients. 
 Our study showed that pursuing a CT abdomen provides little to no additional 
information in light of a negative chest CT scan.  Among the 359 patients who had no detectable 
disease spread to the chest wall, lung, mediastinal or internal mammary lymph nodes, only 1 had 
detectable disease to the abdomen. 
 
Harms and Costs 
 With the benefits of additional knowledge achieved with CT, there are still many risks 
with ordering this test.  These risks are further reasoning for why standard staging protocol is 
necessary for quality improvement, cost-effective medicine, and reducing patient exposure to 
potentially harmful testing.  First, although there is some data that suggests hormesis at low 
levels of exposure, the generally accepted theory is the Linear No Threshold (LNT) theory based 
on extrapolated data from Hiroshima and Nagasaki. Using this theory and the “As Low As 
Reasonably Possible” principle, diagnostic imaging with ionizing radiation is done when the 
risk/benefit ratio shows there is a clear benefit to the patient in terms of medical management 
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based on the information gained from the test.
11
  Furthermore, without a standardized protocol, 
patients risk multiple forms of testing that may lead to additional follow-up imaging.  This 
cumulative exposure may sum to a greater radiation risk for breast cancer patients.
10,12
  
 Secondly, in order to appropriately image liver metastases, patients will receive contrast 
material intravenously prior to CT scanning.  In some cases, contrast material may cause an 
allergic reaction or nephrotoxicity.
12
 Third, the financial cost of additional scanning, travel time, 
and work time lost are growing expenses to the U.S. health care system and the individual 
patient.  Even though pricing for scans are variable between insurance providers and hospital 
systems, the most current hospital charges at UNC for a chest CT with contrast is $2890 with 
professional fee of $155, totaling over $3000 for one scan.  An abdominal and pelvic CT scan 
totals to $2756 with an additional professional fee of $281.  In this study, if the 358 patients with 
negative scans had not undergone abdominal CT in light of their negative chest CT, the total 
savings amounts to $1,087,246.  The cumulative cost and time associated with pursuing 
abdominal CT scans in large numbers of patients are substantial, as exemplified by this value. 
 
Study Limitations  
 This study was a retrospective review of patient medical records.  Several factors may 
have biased our results.  Primarily, it is inherently difficult to fully determine retrospectively why 
a CT may have been ordered for a certain patient; however, to counteract this potential bias, only 
patients with CT scans performed within one month of diagnosis and listed as evaluations due to 
breast cancer diagnosis were included.  It is our belief that the included subjects were scanned as 
part of routine cancer evaluation as opposed to concurrent medical problems or preoperative 
evaluation.   
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 Additionally, CT scans performed at other institutions and reviewed by outside 
physicians were excluded from the study.  This limited a large number of imaging studies that 
could be added to the analysis.  Nevertheless, our sample size was significant, representing 
patients seen at UNCH over a 13-year time period, various presenting stages and 
symptomatology.   
 As this study is retrospective, assessing the clinical impact of the test result, even when 
negative, cannot be fully evaluated.  Furthermore, the effect of routine abdominal CT scanning 
on patient survival cannot be assessed through this database. 
 
Future Research 
 The need for routine imaging with CT chest, abdomen, and pelvis should be reconsidered 
when developing staging protocol based on our study results.  A prospective study including a 
cost-effectiveness analysis as well as well-documented physical examination findings is needed 
to determine if a particular subset of new cancer patients could benefit from CT scanning beyond 
the chest.  Furthermore, additional information concerning routine use of CT pelvis can inform 
future protocol. 
 
Recommendations for CT Imaging and Staging 
 Based on our study results and those of Drotman et. al.
10
 in 2000, we believe that routine 
CT imaging protocol does not require scanning of the chest, abdomen, and pelvis for all new 
breast cancer patients.  In fact, according to our findings, patients with no disease detected in the 
chest wall, lung, mediastinal or internal mammary nodes do not benefit from further imaging 
(including addition of contrast administration for liver evaluation) of the abdomen.  Moreover, 
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routine CT of the pelvis has shown to be of benefit to less than 1% of new breast cancer 
patients.
10 
  The results from these CT scans are rarely relevant to cancer therapy and, therefore, 
of no benefit to patients.  In fact, the exposure to and cost of the testing may be greater potential 
harm to women.   
   
CONCLUSION 
 The routine use of abdominal CT in women with newly diagnosed primary breast cancer 
and no detectable disease beyond the ipsilateral axillary nodes on staging chest CT scan has little 
value with a 99.7% negative predictive value.  Based on this information, we recommend that if 
a negative CT scan of the patient’s chest yields no detectable disease beyond the axillary nodes, 
then further CT imaging of the abdomen is of no additional benefit to the patient and should not 
be performed. 
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TABLES 
Table One: Presence of Metastasis as Detected by CT Scan by Pre-Operative Clinical Stage (n, %)  
Clinical 
Stage (n) 
Axillary 
Nodes
*
 
Chest Wall Internal 
Mammary 
Nodes 
Lung Mediastinal 
Nodes 
Liver
**
 Adrenal 
In Situ (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
I (40) 9 (24.32) 1 (2.50) 0 (0) 0 (0) 2 (5.00) 0 (0) 0 (0) 
IIA (83) 27 (36.99) 3 (3.61) 1 (1.20) 4 (4.82) 1 (1.20) 2 (2.41) 1 (1.20) 
IIB (129) 67 (58.26) 8 (6.20) 1 (0.78) 2 (1.55) 6 (4.65) 2 (1.56) 2 (1.55) 
IIIA (90) 75 (85.23) 4 (4.44) 1 (1.11) 3 (3.33) 4 (4.44) 0 (0) 1 (1.11) 
IIIB (63) 51 (83.61) 11 (17.46) 4 (6.35) 4 (6.35) 4 (6.35) 1 (1.61) 0 (0) 
IV (33) 29 (87.88) 13 (39.39) 1 (3.03) 12 (36.36) 12 (36.36) 7 (21.21) 4 (12.12) 
Total (440) 258 (56.46) 40 (9.10) 8 (1.82) 25 (5.68) 29 (6.59) 12 (2.73) 8 (1.82) 
*Axillary Node data was missing for the following number of patients by stage: in situ (0), Stage I (3), Stage IIA (10), Stage IIB 
(14), Stage IIIA (2), Stage IIIB (2), Stage IV (0).  These patients were subtracted from the study population when calculating the 
percentage of metastases by stage, respectively.  
**Liver data was unavailable for three patients due to lack of contrast for imaging: in situ (0), Stage 1 (0), Stage IIA (0), Stage 
IIB (1), Stage IIIA (1), Stage IIIB (1), Stage IV (0).  These patients were subtracted from the study population when calculating 
the percentage of metastases by stage, respectively. 
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Table Two: Comparison of Disease Detection in the Chest versus Disease Detection in the 
Abdomen (n)
$,#
 
                   Disease in the Abdomen 
  Detected Not Detected  
Disease in the Chest Detected 11 70         81  
 Not Detected 1 358        359  
  12 423         440  
____________________________________________________ 
$Detection of disease in the chest is defined as disease detected beyond the axillary nodes.  
#Positive detection of disease in the chest was defined as disease detected beyond the ipsilateral axillary nodes and present in the 
chest wall, internal mammary nodes, lung, and/or mediastinal nodes.  Positive detection of disease in the abdomen was defined 
as disease detected in the liver and/or adrenals. 
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Table Three: Comparison of Disease Detection in the Chest versus Disease Detection in the 
Liver (n)
%
 
                                             Disease in the Liver 
  Detected Not Detected  
Disease in the Chest Detected 9 70         79  
 Not Detected 1 357        358  
  10 427         437  
_______________________________________ 
%
Liver data was unavailable for three patients due to lack of contrast for imaging.  Their results are not included in the above 
table.  Of these three patients, two had disease present and one did not have disease present in the chest.  None had disease 
detected in the adrenals. 
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Table Four: Comparison of Disease Detection in the Chest versus Disease Detection in the 
Adrenals (n) 
                  Disease in the Adrenals 
  Detected Not Detected  
Disease in the Chest Detected 4 77         81  
 Not Detected 0 359        359  
  4 436         440  
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Table Five: Comparison of Disease Detection in the Chest Wall versus Disease Detection in the 
Abdomen (n) 
         Disease in the Abdomen 
  Detected Not Detected  
Chest Wall Invasion Detected 4 36         40 
 Not Detected 8 392        400 
  12 428         440  
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Table Six: Comparison of Disease Detection in the Internal Mammary (IM) Nodes vs. Disease 
Detection in the Abdomen (n) 
Disease in the Abdomen 
  Detected Not Detected  
Disease in the IM Nodes Detected 2 6         8 
 Not Detected 10 422        432 
  12 423         440  
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Table Seven: Comparison of Disease Detection in the Lungs vs. Disease Detection in the 
Abdomen (n) 
Disease in the Abdomen 
  Detected Not Detected  
Disease in the Lungs Detected 8 17         25 
 Not Detected 4 411        415 
  12 428         440 
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Table Eight: Comparison of Disease Detection in the Mediastinal (MD) Nodes vs. Disease 
Detection in the Abdomen (n) 
Disease in the Abdomen 
  Detected Not Detected  
Disease in MD Nodes Detected 4 25         29 
 Not Detected 8 403        411 
  12 428        440 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
